Cargando…
Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
Immune checkpoint inhibitors have transformed the treatment of cancer. Nonetheless, multiple immune-related adverse events have been reported, including checkpoint inhibitor colitis. Severe colitis can be complicated by ileus, megacolon, intestinal perforation, and death. Current appropriate treatme...
Autores principales: | Perez Del Nogal, Genesis, Patel, Neha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794264/ https://www.ncbi.nlm.nih.gov/pubmed/36600789 http://dx.doi.org/10.14309/crj.0000000000000946 |
Ejemplares similares
-
Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019) -
Successful cyclosporin and ustekinumab combination therapy in a
patient with severe steroid-refractory ulcerative colitis
por: Ganzleben, Ingo, et al.
Publicado: (2020) -
Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022) -
Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2021) -
Successful Treatment of Refractory Autoimmune Enteropathy With Ustekinumab
por: Scheid, Johannes F., et al.
Publicado: (2021)